“For the year, we expect strong double-digit growth for Eliquis overall.”

In context

“design given that there's no donut hole now. And maybe the like given the price point the impact of party design may not be a lot. So in the context of that, how are you thinking about the growth for this brand for this year? . Christopher Boerner: Thanks for the question, Mohit. Adam, do you want to take that? David Elkins: Yes, Thanks Mohit, for the question. As I mentioned, we're going to see favorability with Eliquis this year in the U.S. due to Part D redesign with the elimination of the coverage gap. And so I talked about the dynamics historically, where the first half sales were higher than the second half sales. So we're going to see something very different this year, where Q1 sales will be the lowest quarter for Eliquis, and we'll see higher sales in the second half of the year. For the year, we expect strong double-digit growth for Eliquis overall. And when we look at where we are positioned in the market in the U.S., we have a market share that continues to grow linearly. Our share in the U.S. NBRx is roughly 75% and -- and we know that with Xarelto out of the market, we've got a great opportunity to continue to drive this important brand for the company. Operator: Next question will come from Trang Han of UBS. Unknown Analyst: Just 2, please. So firstly, can you just give us some color on the gross margin cadence for 2025? You touched upon 1Q dynamics, but should we just follow the REVLIMID step downs for the year? -- is there any other considerations that we should think about here? And then just wondering if you can give us any early insights into the access and coverage of Opdivo Quantic -- and any thoughts on the uptake for '2”